Kidney Cancer Research Program (KCRP) Idea Development Award (IDA)

Kidney Cancer Research Program (KCRP) Idea Development Award (IDA) is sponsored by Defense Health Agency Contracting Activity - DHACA. This award supports the development of high-impact ideas that advance the understanding of kidney cancer and ultimately lead to improved patient outcomes, with a focus on well-formulated, testable hypotheses and strong scientific rationale.

This program announcement must be read in conjunction with the General Application Instructions, version CD26_01.

# Program Announcement for the Defense Health Agency # Kidney Cancer Research Program # Funding Opportunity Number: HT942526KCRPIDA # Pre-Application Due: September 14, 2026 # Application Due: September 28, 2026 FY26 Kidney Cancer Idea Development Award 2 Summarizes the funding opportunity , funding details , submission deadlines and review Details eligibility factors for the applicant organization and Principal Investigator Describes the program mission and intent of the Idea Development Award ; provides key award information and considerations ; and outlines funding details Presents the two-step application process and instructions for preparing a pre-application Provides locations for application packages , instructions for submitting pre-applications and full applications , and describes application verification Application Review Information Outlines the processes for application compliance review , pre-application and full application selection/notification, and risk assessment .

Also, details the review criteria for pre-application screening and both tiers of the CDMRP application review process – Peer Review and Programmatic Review Outlines what a successful applicant can expect if recommended for funding References policy requirements for funded research; outlines reporting requirements and restrictions related to Principal Investigator changes and institutional award transfers Outlines criteria for administrative actions including application rejection , modification , Includes a checklist for all full application components to facilitate application submission 33 FY26 Kidney Cancer Idea Development Award 3 • Active SAM.

gov , eBRAP. org and Grants. gov registrations are required for application submission.

User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation. • Read this funding opportunity announcement in the order it is written before beginning to prepare application materials.

It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements. • To support application preparation, additional resources are available including an application process FAQ , a Guide for Intragovernmental & Intramural Applicants and a CDMRP Video Series detailing the application process.

# Who to Contact for Support This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard. Click to be taken to additional guidance and instructions within the General Application Instructions (GAI).

Questions regarding funding opportunity submission requirements, as well as technical assistance related to pre-application or intramural application submission. Grants. gov Support Center International: 1-606-545-5035 FY26 Kidney Cancer Idea Development Award 4 # 1.

Basic Information About the Funding Opportunity Summary: The fiscal year 2026 (FY26) Kidney Cancer Research Program (KCRP) Idea Development Award (IDA) supports the development of high-impact ideas that advance the understanding of kidney cancer and ultimately lead to improved patient outcomes.

The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach. Personnel on the proposed team should have a strong background in kidney cancer research.

Partnering Principal Investigator Option: Supports meaningful and productive partnerships between two investigators, termed the Initiating Principal Investigator (PI) and Partnering PI, collaborating on a single application. Only the Initiating PI will submit a pre-application, but all PIs will need to submit full applications.

The Partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn. Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $7.

8M to fund approximately 8 Idea Development Award applications with total cost caps of $900,000 for the IDA or $1. 2M for the IDA – Partnering PI Option. The maximum period of performance is 3 years.

It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027. Submission and Review Dates and Times Pre-Application (Letter of Intent) Submission Deadline: 5:00 p.

m. Eastern Time (ET), September 14, 2026 Application Submission Deadline: 11:59 p. m.

ET, September 28, 2026 End of Application Verification Period: 5:00 p. m. ET, October 05, 2026 Peer Review: December 2026 Programmatic Review: March 2027 Announcement Type: Initial Funding Opportunity Number: HT942526KCRPIDA Assistance Listing Number: 12.

420 Section Shortcuts FY26 Kidney Cancer Idea Development Award 5 # 2. Eligibility Information Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply , including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities . 2.

1. 2. Principal Investigator Investigators at or above the level of Assistant Professor (or equivalent) may be named by the organization as the Principal Investigator (PI), Initiating PI and/or Partnering PI.

An investigator may be named as a PI on only one FY26 Kidney Cancer Research Program (KCRP) Idea Development Award (IDA) application. Independent investigators affiliated with an eligible organization are eligible to be named PI on the application, regardless of ethnicity, nationality or citizenship status. Cost sharing is not an eligibility requirement.

Awards are made to eligible organizations , not to individuals. Refer to the GAI for additional recipient qualification requirements . Section Shortcuts FY26 Kidney Cancer Idea Development Award 6 The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001).

The CDMRP is the program office managing this FY26 funding opportunity as part of the Kidney Cancer Research Program (KCRP). The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW.

Congress initiated the KCRP in 2017 to provide support for research of high potential impact and exceptional scientific merit. Appropriations for the KCRP from FY17 through FY24 totaled $285 million (M). The FY26 appropriation is $15M.

The KCRP’s vision is to conquer kidney cancer through collaboration and discovery. The mission of the FY26 KCRP is to promote rigorous, innovative, high-impact research in kidney cancer for the benefit of Service Members, their Families, Veterans and the American Public.

Within this context, the KCRP supports research and clinical care that addresses the following KCRP overarching strategic goals: Advance understanding of the biology of kidney cancer. Encourage innovative ideas with high impact. Develop novel therapeutic strategies for the treatment of kidney cancer.

Develop pharmacological, immunological, genetic, microbiome or other interventions. Optimize prognostic or predictive markers to assist with therapeutic decision-making. Repurpose existing and currently approved interventions.

Improve patient care for kidney cancer. Integrate bench research with bedside care and promote translational research. Invest in early-career kidney cancer physicians – next generation.

Facilitate multi-site collaborative clinical research development and clinical trials. Identify strategies to improve outcomes in populations with unequal burden of kidney cancer. Increase research resources and collaborations in the area of kidney cancer.

Invest in innovative research conducted by the next generation of kidney cancer physicians and scientists. Facilitate multi-site collaborative clinical research development and clinical trials. Encourage experts inside and outside the field of kidney cancer to apply knowledge for advancements.

Foster collaborations that cross translational, disciplinary and institutional boundaries. Section Shortcuts FY26 Kidney Cancer Idea Development Award 7 The KCRP Idea Development Award mechanism was first offered in FY17. Since then, 610 Idea Development Award applications were received, and 124 were recommended for funding.

3. 2. Intent of the Idea Development Award The FY26 KCRP IDA mechanism intends to promote development of high-impact ideas that will advance the KCRP vision to conquer kidney cancer.

The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach. Personnel on the proposed team should have a strong background in kidney cancer research. 3.

2. 1. Focus Areas for the IDA To meet the intent of the funding opportunity, applications must address at least one of the FY26 KCRP focus areas, as presented below.

Conduct basic biology research to better understand etiology and cancer progression, metastatic disease, refractory disease and therapeutic resistance, genetic and environmental risk factors, and the prevention of kidney cancer. Identify and develop new strategies for screening, early-stage detection, and accurate diagnosis and prognosis prediction of kidney cancers, including biomarkers and imaging and treatment of early-stage cancers.

Define the biology of rare kidney cancers and develop treatments to improve outcomes and reduce death. Develop novel, less toxic therapeutic strategies for all types of kidney cancer. Identify and implement strategies to improve the quality of life and survivorship for kidney cancer patients.

Identify and implement strategies to enhance outcomes in high-risk kidney cancer patients, including those with limited access to health care, exposure to environmental factors and genetic/biological factors. Increase capacity and multi-disciplinary research through support and development of the next generation of kidney cancer researchers to improve patient care. 3.

2. 2. Kidney Cancer Type Selection for the IDA Applications must address at least one of the kidney cancer disease types, as presented below.

Clear cell renal cell carcinoma (RCC) Multilocular cystic renal neoplasm of low malignant potential Collecting duct carcinoma Section Shortcuts FY26 Kidney Cancer Idea Development Award 8 Oncocytic and chromophobe renal tumors Renal cell carcinoma, unclassified Mucinous tubular and spindle cell carcinoma Clear cell papillary renal cell carcinoma Tubulocystic renal cell carcinoma Acquired cystic disease associated renal carcinoma Eosinophilic solid and cystic renal cell carcinoma Molecularly defined renal carcinomas Succinate dehydrogenase deficient RCC Fumarate hydratase deficient RCC MiT family translocation RCC Elongin C (TCEB1) mutated Anaplastic lymphoma kinase rearranged RCC SMARCB1 deficient renal medullary carcinoma Wilms tumor (nephroblastoma) Von Hippel-Lindau associated with kidney cancer Kidney cancer type - not classified/not applicable 3.

2. 3. Key Elements for the IDA Partnering PI Option: The IDA includes an option for more than one PI.

One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project.

If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section 5.

3, Submission Instructions . Section Shortcuts FY26 Kidney Cancer Idea Development Award 9 Research Approach: The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of kidney cancer. Experimental strategies may be novel or may be based on strong rationale derived from previously published data and/or presented preliminary data.

The feasibility of the research design and methods should be well-defined, and a clear plan articulated as to how the proposed goals of the project can be achieved. Additionally, the application should identify resources and access to those resources, supported by relevant documentation. The application should identify potential problems and pitfalls and address alternative approaches.

If applicable, the application should include a statistical analysis plan for the proposed research, as well as a power analysis to support the design and sample size. Preliminary Data: Preliminary data to support the feasibility of the research hypotheses and approaches are required; however, these data do not need to be derived exclusively from the kidney cancer research field.

Preliminary data may include published or unpublished results from the laboratory of the PI, Initiating PI or Partnering PI, or collaborators named on the application, as well as data from published literature relevant to kidney cancer. Impact: Proposed research projects should address a central critical issue or question in kidney cancer research or clinical care.

High-impact research will, if successful, significantly advance current methods and concepts in at least one of the FY26 KCRP Focus Areas. Personnel: Personnel are considered a crucial element of the FY26 KCRP IDA. The application should demonstrate the investigators’ experience in kidney cancer through the PI’s background, the qualifications of the research team and/or established collaborations.

The application should document collaborations. 3. 2.

4. Other Important Considerations for the IDA In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, the CDMRP does not support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals. Clinical trials are not allowed within this funding opportunity.

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the STROBE , CONSORT , SPIRIT and ARRIVE 2. 0 guidelines.

Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are highly encouraged.

These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American Public.

If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the The following encouragement is broadly applicable across many CDMRP programs, including the KCRP.

A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients.

As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations and submit Section Shortcuts FY26 Kidney Cancer Idea Development Award 10 research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY26 KCRP priorities. The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

Period of Performance : The maximum period of performance is 3 years. Cost Cap : The application’s total costs budgeted for the entire period of performance should not exceed $900,000 . If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate.

Collaborating organizations should budget associated indirect costs in accordance with each organization’s negotiated rate. All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award. The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 3 years.

The appropriateness of the budget for the proposed research will be assessed during peer review. The combined total costs budgeted for the entire period of performance in the applications of the Initiating PI and the Partnering PI should not exceed $1. 2M .

If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization’s negotiated rate. A separate award will be made to each PI’s organization.

The PIs are expected to be partners in the research, and direct cost funding should be divided accordingly unless otherwise warranted and clearly justified. The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 3 years. The appropriateness of the budget for the proposed research will be assessed during peer review.

Direct Cost Restrictions: For this award mechanism, direct costs: May be requested for (not all-inclusive): Travel in support of multi-institutional collaborations. Costs for one investigator (for the Partnering PI Option, one investigator from each partnering application) to travel to one scientific/technical meeting per year.

The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the KCRP Idea Development Award. Section Shortcuts FY26 Kidney Cancer Idea Development Award 11 Must not be requested for: • Costs for travel to scientific/technical meeting(s) beyond the limits stated above. • Clinical trial costs.

Section Shortcuts FY26 Kidney Cancer Idea Development Award 12 # 4. Application Contents and Format 4. 1.

Application Overview Application submission is a two-step process requiring both a pre-application submitted via the Electronic Biomedical Research Application Portal ( eBRAP ) and a full application submitted through eBRAP or Grants. gov. Depending on the submission portal, certain aspects of the application will differ. Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.

Extramural organizations submitting a full application must follow instructions for submission through Grants. gov. 4. 2.

Pre-Application Components The Initiating PI must submit the following pre-application components. Letter of Intent (LOI) (one-page limit): Provide a brief description of the research to be conducted. Include the focus area(s) under which the application will be submitted.

4. 3. Full Application Components Partnering PI Option: The CDMRP requires separate full application package submissions for the Initiating PI and each Partnering PI, even if the PIs are located within the same organization.

The application submission process for the Partnering PI uses an abbreviated full application package. 4. 3.

1. Full Application Components for the PI or Initiating PI Each application submission must include the completed full application package for this program announcement. See Appendix 1 for a checklist of the full application components.

(a) SF424 Research & Related Application for Federal Assistance Form (Grants. gov IMPORTANT: When completing the SF424 R&R, enter the eBRAP log number assigned during pre-application submission into Block 4a – Federal Identifier . Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines in the GAI.

Attachment 1: Project Narrative (12-page limit): Upload as Describe the proposed project in detail using the outline below. Background: Present the ideas and reasoning behind the proposed research. Describe previous experience most pertinent to the application.

Preliminary data are required but need not originate from kidney cancer research. State the FY26 KCRP Focus Area(s) to be addressed. Section Shortcuts FY26 Kidney Cancer Idea Development Award 13 Hypothesis or Objective: State the hypothesis to be tested or the objective to be reached.

Specific Aims: Concisely explain the project’s specific aims. If this research project is part of a larger study, present only the tasks that this award would fund. Research Strategy and Feasibility: Describe the experimental design, methods, and analyses, including appropriate controls, in sufficient detail to allow for scientific evaluation and an assessment of overall project feasibility.

Address potential problem areas, and present alternative methods and approaches. Clearly describe the statistical plan, the rationale for the statistical methodology, and an appropriate power analysis; include the statistical expertise available to support the analysis, if applicable. Consult appropriate guidelines to ensure that relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported.

If human subjects or human anatomical samples will be used, include a plan for the recruitment of subjects or the acquisition of samples, and document the experience of the PI and/or collaborators in recruiting human subjects for similar projects. This award may not be used to conduct clinical trials.

For all applications proposing clinical research , describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study (including a description of the composition of the proposed study population in terms of sex, racial and ethnic group) and an accompanying rationale for the selection of subjects.

Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex, race and ethnicity should be provided as part of the application’s Supporting Documentation ( Attachment 2 ).

Describe how the clinical relevance of the anticipated findings will be determined, and whether the results will be validated in the appropriate patient cohorts, if applicable. Personnel: Explain the degree to which the proposed research demonstrates a critical understanding and in-depth knowledge of kidney cancer.

Partnering PI (for Partnering PI Option only) : Describe the specific contributions of the Partnering PI on the research project, and how the contribution of the partner will support the PI and the proposed project. These contributions should enhance the project’s impact in the kidney cancer field.

Note: Impact should be addressed in Attachment 6 and not in the Project Narrative If the proposed research involves access to military and/or VA patient populations and/or DOW or VA resources or databases, describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

Also include a plan for obtaining any required data sharing, memorandum of understanding or Section Shortcuts FY26 Kidney Cancer Idea Development Award 14 other agreements required to access and publish data. Refer to the GAI, Appendix 4 , for additional considerations. Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.

pdf”. There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

References Cited: List the references cited in the Project Narrative using a standard reference format (include URLs, if available). List of Abbreviations, Acronyms and Symbols: Provide a list of abbreviations, acronyms and symbols.

Facilities, Existing Equipment and Other Resources: Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use.

If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information. Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts.

If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed. Letters of Support (one-page limit per letter is recommended): Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work.

Letters from the PI’s Department Chair, or appropriate organization official, should also confirm that the PI(s) meet eligibility criteria . If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations, databases or DOW resources.

If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space. Sex as a Biological Variable Strategy (two-page limit is recommended): Describe the strategy for how sex will be considered as a biological variable.

This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex.

If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data or other relevant considerations. Refer to the CDMRP Directive on Sex as a Biological Variable in Research for additional information.

Research Sharing Plan: Describe the type of data or research resources (e.g., bio-specimen, analysis tool/software, training material) to be made publicly available as a result of the proposed work.

Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance Section Shortcuts FY26 Kidney Cancer Idea Development Award 15 will be shared with the research community and other affected communities, including clinical research participants.

Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g. for intellectual property, feasibility, cost or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property.

Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users.

In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

Inclusion Enrollment Report (only required if clinical research and/or a clinical trial is proposed) : Provide an anticipated enrollment table(s) for the inclusion of women and minorities using the “ Public Health Service (PHS) Inclusion Enrollment Report ”, a three-page fillable PDF form, that can be downloaded from eBRAP.

The enrollment table(s) should be appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex, race and ethnicity. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity or race (typically classified as exempt from IRB review) are exempt from this requirement.

Do not submit a copy of the National Institutes of Health Data Management and Sharing Plan or duplicate the Data Management Plan, which will be requested only after a recommendation for funding is made. Refer to the CDMRP Directive on Sharing Data and Research Resources for more information about the CDMRP’s expectations for making data and research resources publicly available.

Attachment 3: Technical Abstract (one-page limit): Upload as Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important. Background: Present the ideas and scientific rationale behind the proposed research project.

Focus Areas: State the FY26 KCRP Focus Area(s) to be addressed. Hypothesis/Objective(s): State the hypothesis to be tested and/or objective(s) to be reached. Specific Aims: State the specific aims of the study.

Study Design: Describe the study design, including appropriate controls. Impact: Describe how the proposed research will yield critical discoveries, new avenues of investigation, or major advancements to prevent or cure kidney cancer. Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.

pdf”. The lay abstract should address the points outlined below in a manner that is readily understood by readers without a background in science or medicine . Avoid overuse of scientific jargon, acronyms and abbreviations.

Do not duplicate the technical abstract. Section Shortcuts FY26 Kidney Cancer Idea Development Award 16 Summarize the objectives and rationale for the proposed research. State the FY26 KCRP Focus Area(s) to be addressed.

What population will the research help, and how will it help them? What are the potential clinical applications, benefits and risks of the anticipated outcomes? If the research is too basic for clinical applicability, describe the interim outcomes expected and their applicability to the field.

What is the projected time it may take to achieve a clinically relevant outcome? What are the likely contributions of the proposed research project to advancing research, patient care and/or quality of life? Describe the impact that the proposed research project results might have on the field of kidney cancer research and/or patient care in the short term and/or long term for to Service Members, Veterans and/or their Families.

Attachment 5: Statement of Work (three-page limit): Upload as “SOW. pdf”. Refer to eBRAP for the Suggested SOW Format .

Each PI must submit an identical copy of a jointly created SOW. The specific contributions of the Initiating PI and the Partnering PI should be clearly noted for each task. For guidance on preparing the SOW, refer to either the Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work or Example: Assembling a Generic Statement of Work , whichever is most appropriate for the proposed effort.

Include milestones for data or research resource(s) sharing. Attachment 6: Impact Statement (one-page limit): Upload as “Impact. pdf”.

This section should be written in a manner readily understood by readers without a background in science or medicine. Overly technical jargon should be avoided and technical terms, if any, should be defined. Describe how the proposed research is relevant to at least one of the FY26 KCRP Focus Areas in a way that is consistent with the program’s goals.

Describe the short-term impact: Detail the anticipated outcome(s)/product(s) (intellectual and/or tangible) that directly result from the proposed research to drive the kidney cancer field forward and support new avenues for research or clinical care. Describe the long-term impact: Explain the potential long-term impact of this study on the field of kidney cancer research and/or patient care.

Describe how the proposed research will, whether in the short or long term, lead to an original and important contribution toward advancing basic, translational, or clinical kidney cancer research, or to improvements in the quality of life of individuals with kidney cancer. If applicable, describe how the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.

Section Shortcuts FY26 Kidney Cancer Idea Development Award 17 Attachment 7: Animal Research Plan (three-page limit): Upload as “AnimalResPlan. pdf”. (Attachment 7 is only applicable and required for applications proposing animal studies.)

If the proposed study involves animals, a summary describing the animal research that will be conducted must be included in the application. Consult the ARRIVE guidelines 2. 0 to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported.

The Animal Research Plan may not be an exact replica of the protocol(s) submitted to the Institutional Animal Care and Use Committee (IACUC). The Animal Research Plan should address the following points to achieve reproducible and rigorous results for each proposed animal study: Briefly describe the